Bavarian Nordic indsender supplerende ansøgning til de amerikanske sundhedsmyndigheder om godkendelse af frysetørret koppe- og mpoxvaccine
May 31, 2024 10:33 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 31. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indsendt en supplerende registreringsansøgning til de amerikanske sundhedsmyndigheder, U.S. Food and...
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
May 31, 2024 10:33 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA)...
Bavarian Nordic og CEPI indgår partnerskab om mpox-vaccinationer i Afrika
May 30, 2024 07:30 ET
|
Bavarian Nordic A/S
Forsøg i Afrika vil potentielt understøtte godkendelse af mpox-vaccine i endemiske lande samt udvidelse af de nuværende godkendelser til at omfatte børn CEPI har tildelt USD 6,5 mio. i støtte...
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
May 30, 2024 07:30 ET
|
Bavarian Nordic A/S
African trial could potentially support licensure of mpox vaccine in endemic countries and expansion of current regulatory approvals to include childrenCEPI has awarded USD 6.5 million in funding to...
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
May 22, 2024 04:07 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 22. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har forhøjet sin aktiekapital med nominelt DKK 187.020 som følge af medarbejderes udnyttelse af...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
May 22, 2024 04:07 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 187,020 as a consequence of employees’ exercise...
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram samt ophør af aktietilbagekøbsprogram
May 21, 2024 17:25 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 21. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 8. maj 2024, nu er afsluttet, da det planlagte antal...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
May 21, 2024 17:25 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the...
Laurence de Moerlooze fratræder som EVP og Chief Medical Officer i Bavarian Nordic
May 21, 2024 08:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 21. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Laurence de Moerlooze har valgt at fratræde sin stilling som Executive Vice President og Chief Medical Officer i...
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
May 21, 2024 08:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the...